Research Articles

Liposomal Doxorubicin in the treatment of breast cancer patients: a review

Authors: Lao J, Madani J, Puértolas T, Alvarez M, Hernández A, Pazo-Cid R, Artal A, Antón Torres A
Publication: J Drug Deliv, PubMed (PMID: 23634302)
Date: March 26, 2013

Detection of early sub-clinical trastuzumab-induced cardiotoxicity in breast cancer patients

Authors: Dores H, Abecasis J, Correia MJ, Gândara F, Fonseca C, Azevedo J, Arroja I, Martins A, Mendes M
Publication: Arq Bras Cardiol, PubMed (PMID: 23525273)
Date: March 22, 2013

Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: is it necessary?

Authors: Gill SE, Savage K, Wysham WZ, Blackhurst DW, Winter WE, Puls LE
Publication: Gynecol Oncol, PubMed (PMID: 23523653)
Date: March 21, 2013

Severe cardiotoxicity associated with ixabepilone use in metastatic breast cancer

Authors: Santiago MJ, Hayes BD, Butler KH
Publication: Ann Pharmacother, PubMed (PMID: 23512664)
Date: March 19, 2013

Chemotherapy-related cardiotoxicity

Authors: Aggarwal S, Kamboj J, Arora R
Publication: Ther Adv Cardiovasc Dis, PubMed (PMID: 23487044)
Date: March 13, 2013

Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: A north American perspective

Authors: Orgel E, Zung L, Ji L, Finklestein J, Feusner J, Freyer DR
Publication: Pediatr Blood Cancer, PubMed (PMID: 23441080)
Date: February 25, 2013

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children

Authors: Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR; CPNDS Consortium
Publication: Pediatr Blood Cancer, PubMed (PMID: 23441093)
Date: February 25, 2013